新天药业(002873) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥177,321,934.57, a decrease of 15.06% compared to ¥208,755,879.11 in the same period last year[5] - Net profit attributable to shareholders was ¥15,571,957.55, down 37.94% from ¥25,092,336.81 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 177,321,934.57, a decrease of 15.06% compared to CNY 208,755,879.11 in Q1 2023[21] - Net profit for Q1 2024 was CNY 15,571,957.55, representing a decline of 37.83% from CNY 25,092,336.81 in Q1 2023[23] - Basic earnings per share for Q1 2024 were CNY 0.0673, down from CNY 0.1082 in the same period last year[24] Cash Flow - The net cash flow from operating activities increased significantly to ¥20,608,457.90, compared to a negative cash flow of ¥311,487.89 in the previous year, marking a 6,716.13% improvement[5] - Total cash inflow from operating activities decreased to ¥214,854,966.78 from ¥247,795,270.83, a decline of approximately 13.3%[26] - Cash outflow from operating activities decreased to ¥194,246,508.88 from ¥248,106,758.72, a reduction of about 21.7%[26] - Cash flow from investing activities resulted in a net outflow of ¥13,487,992.39, compared to a net outflow of ¥34,345,766.82 in the previous period, showing a decrease of 60.7%[26] - Cash inflow from financing activities increased to ¥181,000,000.00 from ¥127,000,000.00, representing an increase of approximately 42.5%[26] - The net cash flow from financing activities was negative at -¥4,751,467.96, compared to a positive flow of ¥50,602,908.34 in the previous period[26] - The ending cash and cash equivalents balance increased to ¥140,605,931.76 from ¥116,613,200.61, reflecting a growth of about 20.6%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,902,648,986.91, a slight decrease of 0.48% from ¥1,911,798,773.73 at the end of the previous year[5] - Total liabilities increased to CNY 887,105,095.07, compared to CNY 798,467,640.63 in the previous year[20] - Current liabilities rose to CNY 644,542,451.56, an increase of 16.01% from CNY 555,423,976.37 in Q1 2023[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 18,946, with the largest shareholder holding 33.59% of the shares[11] - The company initiated two rounds of share repurchase plans, utilizing a total of RMB 113.71 million to stabilize stock prices and enhance market confidence[15] - As of the end of the reporting period, the company repurchased a total of 8.81 million shares, accounting for 3.80% of the total share capital, with a total expenditure of RMB 753.04 million[16] - The total amount spent on share repurchases during the first quarter was RMB 38.41 million, representing 1.74% of the total share capital[15] - The company adjusted its share repurchase budget to a range of RMB 50 million to RMB 100 million in the latest plan[16] Research and Development - Research and development expenses increased by 31.17% to ¥5,233,578.17 from ¥3,990,027.82 in the previous year, indicating a focus on innovation[9] - Research and development expenses increased to CNY 5,233,578.17, up 31.12% from CNY 3,990,027.82 in Q1 2023[21] Operational Metrics - The company recorded a total of ¥856,747.40 in non-recurring gains and losses during the reporting period[7] - The weighted average return on equity decreased to 1.45% from 2.20% in the previous year, reflecting a decline in profitability[5] - Employee compensation payments rose to ¥89,158,397.69 from ¥49,916,984.61, an increase of about 78.5%[25] - Other cash payments related to operating activities decreased significantly to ¥58,280,809.86 from ¥133,581,053.80, a reduction of approximately 56.4%[25] - Accounts receivable decreased to RMB 213.80 million from RMB 226.45 million, indicating a reduction of approximately 5.58%[18] - Inventory increased to RMB 192.23 million from RMB 184.33 million, reflecting a growth of about 4.88%[18] Strategic Initiatives - The company plans to acquire equity in Huilun Pharmaceutical, which will become a wholly-owned subsidiary upon completion of the transaction[16] - The company aims to enhance shareholder value and maintain sustainable development through strategic investments and acquisitions[15] - The company’s financial strategy focuses on maintaining liquidity while pursuing growth opportunities through acquisitions and market expansion[15]